Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CDK4 | P11802 | 16/20 | 1.00 |
| ▸ | CCND1 | P24385 | 16/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 10/20 | 1.00 |
| ▸ | CCND3 | P30281 | 3/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 3/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.83 |
| ▸ | CDK9 | P50750 | 2/20 | 0.83 |
| ▸ | TTK | P33981 | 1/20 | 0.79 |
| ▸ | FLT3 | P36888 | 1/20 | 0.79 |
| ▸ | CCNH | P51946 | 1/20 | 0.79 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.79 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.79 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15249268 | 1.00 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL15249269 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551643 | 0.94 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL10082029 | 0.94 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL20980211 | 0.92 | CDK2 (0.86) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL31061162 | 0.91 | CDK2 (0.85) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29356370 | 0.91 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29763763 | 0.91 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL10082028 | 0.91 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29514690 | 0.90 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705301-A2 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705300-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705302-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4547666-A1 | METHODS FOR TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12291539-B2 | KRAS G12C inhibitors | FRONTIER MEDICINES CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION | 2025-04-24 | — | — | US | disclosed |
| US-20250019387-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION | 2025-01-16 | — | — | US | disclosed |
| EP-4476220-A1 | METHODS FOR TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024229447-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229442-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229444-A2 | MUTANT KRAS INHIBITORS AND USES THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2024-11-07 | — | — | WO | disclosed |
| EP-3849537-B1 | COMBINATION THERAPIES | MIRATI THERAPEUTICS INC (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-111837146-B | G1T38 excellent dosing regimen | G1治疗公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-4426695-A1 | KRAS G12C INHIBITORS | Frontier Medicines Corporation (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2024006445-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023150394-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291539-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | CDK2 116/4885CDK4 160/4885CCND1 520/4885 |
| US-20250129103-A1 | METHODS FOR TREATMENT OF CANCER | KRAS, HRAS, TP53 | CDK2 209/4885CDK4 64/4885CCND1 828/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CDK2 116/4885CDK4 160/4885CCND1 520/4885 |
| US-20250019387-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CDK2 116/4885CDK4 160/4885CCND1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.